spacer
home > epc > spring 2009 > at the heart of safety
PUBLICATIONS
European Pharmaceutical Contractor

At the Heart of Safety

Some prominent examples of drugs recently withdrawn because of their potential to increase cardiac risk have lately led to a broad discussion about the need to have an early and thorough cardiac evaluation in clinical development for all drugs. So far, the most efficient and effective method of evaluating the cardiac effects of drugs is to analyse drug-induced changes in the surface electrocardiogram (ECG), although the ECG is certainly not a perfect biomarker.

The Food and Drug Administration (FDA) and the European Medicines Agency have recently published their recommendations for ECG QT/QTc studies to evaluate the proarrhythmic potential of non-anti-arrhythmic drugs (1). The QT interval represents the ventricular depolarisation and following repolarisation of the heart-cycle. The QT interval is commonly measured from the beginning of the QRS complex (Q-Point) to the end of the T-wave. Some drugs have the ability to delay cardiac repolarisation, which can be measured as prolongation of the QT (QTc) interval in the electrocardiogram (ECG). A delay in cardiac repolarisation favours the development of arrhythmias, such as Torsade de Pointes (TdP). A main feature of TdP is a significantly prolonged QT interval – unfortunately, TdP may degenerate into ventricular fibrillation, leading to sudden cardiac death. But the threshold level of regulatory concern is around 5ms, as evidenced by an upper bound of the 95 per cent confidence interval around the mean effect on QTc of 10ms – this requires very accurate acquisition and analysis of the 12 lead surface ECG (1).

 


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Tosja K Zywietz, Head Scientist of Cardiac Technology at Cardinal Health Research Services, started his commercial career with The Boston Consulting Group as a Strategy Consultant. He holds a PhD in Theoretical Physics from the Fritz-Haber-Institute in Berlin. Over the last few years, he has gained extensive experience in developing new technology and methods for cardiac safety trials. He is the co-founder of Biosigna, specialising in ECG services for the pharmaceutical industry, which was recently acquired by Cardinal Health.

spacer
Tosja Zywietz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control

Berlinger & Co AG

There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement